AbbVie (NYSE:ABBV) Releases FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 13.950-13.990 for the period, compared to the consensus estimate of 13.950. The company issued revenue guidance of $67.8 billion, compared to the consensus revenue estimate of $67.6 billion. AbbVie also updated its Q4 2026 guidance to 3.830-3.870 EPS.

AbbVie Stock Performance

NYSE ABBV opened at $290.02 on Tuesday. The firm has a market capitalization of $512.41 billion, a P/E ratio of 49.74, a PEG ratio of 1.31 and a beta of 0.24. The stock has a 50-day simple moving average of $269.81 and a two-hundred day simple moving average of $237.57. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $298.74.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.86 earnings per share. As a group, analysts forecast that AbbVie will post 13.92 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is 119.10%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ABBV shares. Weiss Ratings upgraded shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. HSBC raised their price target on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $275.00 price objective on shares of AbbVie in a report on Monday. Leerink Partners upped their price objective on shares of AbbVie from $309.00 to $342.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, Cantor Fitzgerald increased their target price on shares of AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $294.67.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its fiscal 2026 adjusted EPS outlook to $13.95-$13.99, above the prior consensus midpoint, and forecast revenue of $67.8 billion, ahead of the $67.6 billion consensus. Growth from Skyrizi, Rinvoq and neuroscience products is helping offset Humira’s decline. ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
• Positive Sentiment: Multiple analysts raised their price targets following AbbVie’s strong third-quarter results, including RBC to $330, Cantor Fitzgerald to $325, Canaccord Genuity to $338, Leerink Partners to $342 and Morgan Stanley to $346. The firms maintained bullish ratings. Analysts Increase Forecasts on AbbVie
• Positive Sentiment: AbbVie expanded a global license agreement with Brise Pharmaceuticals for next-generation migraine therapies. The deal could be worth up to approximately $757 million and follows positive Phase 3 migraine data published in The Lancet Neurology. AbbVie License Deal With Brise
• Positive Sentiment: AbbVie won a lawsuit challenging certain drug-price-control actions by the U.S. Department of Health and Human Services, potentially reducing regulatory and pricing pressure. AbbVie Wins Drug Price Control Lawsuit
• Neutral Sentiment: Allergan Aesthetics will present nine research abstracts at ASDS 2026, covering aesthetic treatment after medical weight loss, BOTOX Cosmetic and investigational trenibotulinumtoxinE. The event supports AbbVie’s long-term aesthetics pipeline but is unlikely to materially affect near-term earnings. Allergan Aesthetics ASDS 2026 Research
• Negative Sentiment: AbbVie’s fourth-quarter EPS guidance of $3.83-$3.87 is below the $3.89 consensus estimate, despite revenue guidance of $18.4 billion exceeding expectations. The modest earnings shortfall may be the clearest near-term pressure on the shares.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.